Pumitamig  (Synonyms: PM-8002; BNT-327)

Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy^[1].

IgG1-kappa-VH

Human IgG1 kappa, Isotype Control

Human

PD-L1 & VEGF

Pumitamig features a bispecific molecular structure design, consisting of a humanized anti-PD-L1 single-domain antibody (VHH) fused to an anti-VEGF-A IgG1 antibody carrying Fc-silencing mutations.
Pumitamig can specifically bind to two targets, PD-L1 and VEGF-A, simultaneously; this allows it to directly block the PD-1/PD-L1 interaction, relieve the immunosuppression mediated by this pathway to activate cytotoxic T lymphocytes, and directly inhibit the proliferation of vascular endothelial cells by neutralizing VEGF-A, thereby achieving dual in vitro activities of immune activation and anti-angiogenesis at the levels of target binding and pathway regulation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pumitamig (5-20 mg/kg) induces 47.6% and 71.4% tumor growth inhibition at doses of 5 mg/kg and 20 mg/kg, respectively, in C57BL/6 mice inoculated with MC38 colon cancer cells overexpressing human TROP2^[1].
Pumitamig (5-20 mg/kg) induces 69.5% and 88.1% tumor growth inhibition at doses of 5 mg/kg and 20 mg/kg, respectively, in C57BL/6 mice inoculated with human HER2-overexpressing MC38 colon cancer tumors^[1].
Pumitamig induces 78.2% tumor growth inhibition in B-NDG B2M KO Plus mice implanted with human A375 melanoma xenografts and infused with human PBMCs^[1].
Pumitamig induces 53%, 59.2%, and 45% tumor growth inhibition, respectively, in B7H3-overexpressing CT26 colon cancer-bearing BALB/c mice, human HER3-overexpressing MC38 colon cancer-bearing C57BL/6 mice, and B-NDG B2M KO Plus mice bearing human HER2-overexpressing A375 melanoma xenografts and infused with human PBMCs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

29126  [NCBI] & 7422  [NCBI]

Q9NZQ7 & P15692

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

172.48 kDa

Liquid

Colorless to light yellow

[Pumitamig]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-kappa-VH

• 
  Immobilized hu-PD-L1-ECD-His can bind PM-8002. The EC₅₀ for this effect is 116.7 ng/mL.
• 
  Immobilized rhVEGF can bind PM-8002. The EC₅₀ for this effect is 19.39 ng/mL.
• 
  Flow Cytometry analysis of Hela cells labelling PD-1 (red) with Pumitamig (anti-PD-1) (HY-P991097). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99991, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
• 
  Flow Cytometry analysis of K562 cells labelling VEGF (red) with Pumitamig (HY-P991097). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Hamilton E P, et al. Activity of BNT327/PM8002 (PD-L1 x VEGF-A bispecific antibody) in combination with BNT325/DB-1305 (TROP2 ADC) in solid tumors: Early preclinical and clinical evidence to support BNT327+ ADC combinations[J]. Cancer Res, 2025, 85: 648.